We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Recipharm and Pharmanest Form Collaboration
News

Recipharm and Pharmanest Form Collaboration

Recipharm and Pharmanest Form Collaboration
News

Recipharm and Pharmanest Form Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Recipharm and Pharmanest Form Collaboration"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Recipharm Karlskoga AB and Pharmanest AB have announced the formation of a new pharmaceutical manufacturing contract for SHACT.

Every year, millions of women around the world experience pain and discomfort during IUD insertion (intrauterine contraception). There are few treatment options with proven efficacy and safety available to these women.

SHACT is a product based on an innovative formulation of lidocaine, a well-known anesthetic, and a proprietary application device developed to simplify topical application in the cervix and uterus.

SHACT has demonstrated convincing Phase II efficacy data as local anesthesia in connection with IUD insertion and also recently reported positive data from a hysteroscopy study.

Recipharm and Pharmanest have reached a milestone in their existing collaboration and Pharmanest is now preparing its candidate SHACT for launch.

Additionally, the companies have reached a long term agreement for commercial manufacturing, with the precise product launch date to be announced later.

Jointly, the two companies will offer commercial supply to any market that Pharmanest determine to enter for supply and sales of their first pharmaceutical product SHACT.

Ingela Palmkvist, General Manager at Recipharm in Karlskoga, commented: “I really look forward to closely following the introduction of this product to various markets. Indeed, I believe it will make a highly significant difference to patients.”

Gunilla Lundmark, CEO at Pharmanest said: “I am very pleased that Pharmanest and Recipharm have entered into this new collaboration following the product development success achieved to date. Given the strong clinical data we are now rapidly moving toward commercialization. We look forward to working closely with Recipharm for the commercial manufacture of the product and, indeed, to pooling our respective skills and capabilities to supply the pharmaceutical product to key target markets.”

Advertisement